Table 7.
Salvage CT Associating CT and BV and Salvage Therapy with BV Alone
| Author | N | Refr | Rel After HDC | CT/PET Evaluation | ORR | CR | ORR Refr | CR Refr | OS | PFS | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BV alone |
Younes,16 2012 §Chen17 2015 |
102 | / | 100% | PET | 75% | 34% | / | / | / | / |
| Rothe,88 2012 | 45 | 64% | 87% | PET | 60% | 22% | / | / | / | / | |
| Zinzani,89 2013 | 65 | 69% | 92% | PET | 70% | 21% | / | / | / | / | |
| Gibb,90 2013 | 18 | 71% | 33% | PET | 72% | 17% | / | / | / | / | |
| Chen,17 2015 | 37 | 65% | / | PET | 68% | 35% | 67% | / | / | / | |
| ¤Moskowitz,18 2015 | 47 | 56% | / | PET | 76% | 76% | / | / | 95% @ 2 y | 80% @ 2 y | |
| ^Perrot,91 2016 | 240 | 56% | 59% | CT or PET (78%) | 64% | 33% | 58% | / | / | 57% @ 2 y | |
| Eyre,32 2018 | 99 | / | / | CT or PET | 53% | 29% | / | / | 70% @ 2 y | 68% @ 2 y | |
| BV-Benda | LaCasce,19 2018 | 55 | 50% | / | PET | 92% | 73% | 85% | 64% | 67% @ 3 y | 60% @ 3 y |
| O’Connor,20 2018 | 65 | / | 63% | PET | 71% | 32% | / | / | / | / | |
| Kalac,21 2018 | 10 | 100% | / | PET | 100% | 90% | / | / | / | / | |
| Picardi,22 2019 | 20 | 55% | 25% | PET | 100% | 100% | / | / | / | / | |
| Broccoli,23 2019 | 40 | 50% | / | PET | 80% | 75% | 75% | 65% | 88% @ 2 y | 67% @ 2 y | |
| Iannitto,24 2020 | 47 | 51% | 25% | PET | 79% | 49% | / | / | 72% @ 2 y | 60% @ 2 y | |
| BV-CT | Michallet,28 2015 GVD | 11 | 45% | / | PET | 100% | 73% | / | / | 60% @ 1 y | / |
| Abuelgasim,25 2019 IGEV | 28 | 43% | / | PET | 96% | 71% | / | / | 87% @2 y | 73% @ 2 y | |
| Garcia-Sanz,27 2019 ESHAP | 66 | 40% | / | PET | 91% | 70% | / | 37% | 91% @ 2.5 y | 71% @ 2.5 y | |
| Hagenbeek,26 2019 DHAP | 12 | / | / | PET | 92% | 92% | / | / | / | / | |
| O-CT | Martinez,15 2016 ESHAP | 62 | 32% | / | PET | 73% | 44% | 50% | / | 88% @ 2 y | 46% @ 2 y |
Notes: §Long-term follow-up of Younes 2012. ^15% of the patients received allogeneic stem cell transplantation. ¤In this study, after BV alone, the CR rate was 27%. Seventy-three percent of non-responding patients received CT, and 73% obtained CR. Overall, after BV and CT, 76% obtained PET negativity.
Abbreviations: O, ofatumumab; Rel, relapse; Refr, refractory; CT, chemotherapy; IGEV, Ifosfamide, gemcitabine, vinorelbine; GVD, gemcitabine, vinorelbine, pegylated liposomal doxorubicin; DHAP, dexamethasone, cytarabine, cisplatin; ESHAP, etoposide, cytarabine, cisplatin, methylprednisolone.